| |MARCH 20266VIVID OUTLOOKHow PLI Scheme is Reshaping India's Drug Production FutureMass Spectrometry in Biomarker Discovery for Early Disease DetectionBalancing Innovation and Affordability in Medical Solutions for IndiaVikram Aditya Sehgal, Director ­ Finance, Centrient IndiaNandakumar Kalathil, AVP - Sales (India), Agilent TechnologiesRajiv Gupta, Country Business Leader (Healthcare Business), 3M India202832VANTAGE POINT12THOUGHT CENTRAL14AFTERWORDHow Digital Maturity Is Powering Pharma's GMP EvolutionSandeep Raktate, President - Operations (India & Ireland), Amneal PharmaceuticalsIndia's Rare Disease Shift Driven by PRIP & PLI PoliciesBridging Collaboration Gaps to Boost India's Pharma DiscoverySaransh Chaudhary, President - Global Critical Care (Venus Remedies) & CEO,Venus Medicine Research CentreDr. Sadhna Joglekar, Senior VP & Head - Global Drug Development India, Novartis34
< Page 5 | Page 7 >